A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy
Open accessThe DOI matches its Crossref record; 26 of the 29 references it cites were found in a registry or an index.
Abstract
In Brief Objective: To compare outcomes with early corticosteroid withdrawal (CSWD) and chronic low dose corticosteroid therapy (CCS). Summary Background Data: Final, 5-year results from the first randomized, double-blind, placebo-controlled trial of early CSWD (at 7 days posttransplant) are presented. Methods: Adult recipients of deceased and living donor kidney transplants without delayed graft function were randomized to receive prednisone (5 mg/d after 6 months posttransplant) or CSWD. Blinding was maintained for 5 years. This clinical trial is registered at www.clinicaltrials.gov (NCT00650468). Results: Results in 386 patients CSWD (n = 191), CCS (n = 195) are presented (CSWD; CCS). No differences were observed at 5 years in the proportion of patients experiencing: primary end point (composite of death, graft loss, or moderate/severe acute rejection) (30/191 (15.7%); 28/195 (14.4%)), patient death (11/191(5.8%);13/195 (6.7%)), death-censored graft loss (11/191 (5.8%); 7/195(3.6%)), biopsy confirmed acute rejection (BCAR) (34/191 (17.8%); 21/195 (10.8%), P = 0.058), moderate/severe acute rejection (15/191 (7.9%); 12/195 (6.2%)). Kaplan Meier analyses of the primary end point and its components also showed no differences; but BCAR was higher with CSWD (P = 0.04). Increased BCAR episodes were primarily corticosteroid-sensitive Banff 1A rejections: the incidence of antibody-treated BCAR was similar between groups (11/191 (5.8%); 13/195 (6.7%)). No differences in renal function were observed at 5 years: mean serum creatinine (1.5 ± 0.6; 1.5 ± 0.7 mg/dL), or Cockroft Gault calculated creatinine clearance (58.6 ± 19.7; 59.8 ± 20.5 mL/min). CSWD was associated with improved serum triglycerides (evaluated by mean and median change from baseline) at all time points (except at 5 years measured by mean change). Weight change also demonstrated changes favoring CSWD (median change from baseline at 5 years: 5.1 vs. 7.7 kg, P = 0.05). New onset diabetes after transplant (NODAT) was similar with respect to proportions who required treatment (23/107 (21.5%)); 18/86 (20.9%); however, fewer CSWD patients required insulin for NODAT at 5 years (4/107 (3.7%)); 10/86 (11.6%), P = 0.049). Changes in HgA1c values (from baseline) were lower in CSWD patients at all time points except 4 years. Conclusions: Early CSWD, compared with CCS, is associated with an increase in BCAR primarily because of mild, Banff 1A, steroid-sensitive rejection, yet provides similar long-term renal allograft survival and function. CSWD provides improvements in cardiovascular risk factors (triglycerides, NODAT requiring insulin, weight gain). Tacrolimus/MMF/antibody induction therapy allows early CSWD with results comparable to long-term low dose (5 mg/d) prednisone therapy. Final results from the first prospective, randomized, placebo-controlled, double-blind trial of early corticosteroid withdrawal in kidney transplantation are reported. This trial, which was blinded for 5 years, demonstrates that early corticosteroid withdrawal (under induction therapy with tacrolimus/mycophenolate mofetil therapy), as compared to chronic corticosteroid therapy, provides similar patient survival, and renal allograft survival and function. Early corticosteroid withdrawal was associated with increased acute rejection risk, but also provided improvements in several corticosteroid-related morbidities including post-transplant diabetes, weight gain, and triglycerides.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other more unique risk factors in this population include genetic polymorphisms, polycystic kidney disease, hepatitis C, and cytomegalovirus status.1579–1581”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1581]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
Immunosuppression: Evolution in Practice and Trends, 1994–2004
Meier-Kriesche, H.-U., Li, S., Gruessner, R. W. G., Fung, J. J., Bustami, R. T., Barr, M. L., & Leichtman, A. B. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01270.x · Cited by 559
&NA; (1999) · Transplantation · doi:10.1097/00007890-199912270-00009 · Cited by 277
Rostaing, L., Cantarovich, D., Mourad, G., Budde, K., Rigotti, P., Mariat, C., Margreiter, R., Capdevilla, L., Lang, P., Vialtel, P., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000154915.20524.0a · Cited by 249
Effects of Low-Dose Prednisone on Bone Metabolism
Ton, F. N., Gunawardene, S. C., Lee, H., & Neer, R. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041125 · Cited by 223
Vanrenterghem, Y., Lebranchu, Y., Hen??, R., Oppenheimer, F., & Ekberg, H. (2000) · Transplantation · doi:10.1097/00007890-200011150-00015 · Cited by 213
Sinclair, N. (1992) · Europe PMC (PubMed Central) · Cited by 203
Ratcliffe, P., Dudley, C., Higgins, R., Firth, J., Smith, B., & Morris, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)02510-x · Cited by 178
Research works printed but not linked: 2
- Sinclair, 1992, Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts., Can Med Assoc J, 147, 645
- Woodle, 2005, A randomized, prospective, multicenter study of thymoglobulin in renal transplantation for induction and minimization of steroids (TRIMS)., Am J Transplant, 5, 571
Cited by
Items 401–472 of 472
Optimal use of corticosteroids in nephrology
Sprangers, B. (2014) · Journal of Translational Internal Medicine · doi:10.4103/2224-4018.135602
Antilymphocyte Induction: Effective Immune Suppression When the Stakes Are High?
Gaber, A. O. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.04.018
Self-citationMiura, M., Ogawa, Y., Kubota, K., Harada, H., Shimoda, N., Seki, T., Hirano, T., & Nonomura, K. (2009) · Clinical Transplantation · doi:10.1111/j.1399-0012.2009.01002.x
Transplantation sans corticostéroïdes
Villemain, F. (2009) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(09)73426-1
New-onset diabetes after transplantation: focus on strategies to reduce risk
Sharif, A. (2011) · Diabetes Management · doi:10.2217/dmt.11.10 · Cited by 1
Diabetes nach Nierentransplantation
Türk, T. R., & Witzke, O. (2011) · Der Nephrologe · doi:10.1007/s11560-010-0511-5
Glukokortikoidi v nefrologiji I: farmakologija in stranski učinki
Pajek, J., & Jensterle, M. (2015) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1236 · Cited by 1
Posttransplantation Monitoring and Outcomes
Gill, J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4617-0.00062-5
Authors' Reply to Knight and Morris
Sprangers, B., & Vanrenterghem, Y. F. C. (2011) · Transplantation · doi:10.1097/tp.0b013e318208e6f2
L'ipertensione arteriosa nel follow-up del trapianto renale
Angelini, D., Parrini, M., & Rosati, A. (2011) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2011.1472
Osteoporosis in Organ Transplant Patients
Furst, J. R., & Shane, E. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-34238-2_11
Immunosuppression: Induction, Maintenance, and Steroid Avoidance Protocols
Kaiser, B. A., & Polinsky, M. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-08049-9_32-1
Hypertension in the Kidney Transplant Recipient
Varas, S., & Vella, J. P. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_8
UNGRADED SUGGESTIONS FOR CLINICAL CARE IMPLEMENTATION AND AUDIT
Pilmore, H., & Manley, P. W. (2012)
Daloul, R., Gupta, S. D., & Brennan, D. C. (2017) · Current Transplantation Reports · doi:10.1007/s40472-017-0147-8
Maintenance Immunosuppression in Kidney Transplantation
Cortinovis, M., Remuzzi, G., & Perico, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00020-5
Post-Kidney Transplant Modification of Cardiovascular Risk
Ghanta, M., Rao, S., Lee, I. T., & Constantinescu, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-56042-7_25
THE INDIVIDUAL TAILORING OF IMMUNOSUPPRESSIVE THERAPY AFTER HEART TRANSPLANTATION
Николаевна, К. Н., Попцов, В. Н., & Шевченко, А. О. (2018) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2018-1-127-137
Rostaing, L. P. E. (2017) · Open Access Journal of Urology & Nephrology · doi:10.23880/oajun-16000124
Kidney Transplantation and Diabetic Nephropathy
Kers, J., & Bemelman, F. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_26
Baek, C. H., Kim, C.-D., Lee, D. R., Kim, Y. H., Yang, J., Kim, B. S., Lee, J. S., Han, S. Y., Kim, S. W., Lee, S., et al. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.01.057
Immunosuppressive Pharmacotherapy
Gabardi, S., & Chandraker, A. K. (2012) · Wiley eBooks · doi:10.1002/9781118483664.ch10
Complications of Immunosuppression
McDermott, J. K. (2019) · Organ and tissue transplantation · doi:10.1007/978-3-319-33280-2_21-1
Induction and Maintenance Immunosuppressants in Sensitized Renal Allograft Recipients
Kong, J. M. (2019) · Springer eBooks · doi:10.1007/978-981-10-7046-4_4
Reshetnik, A. (2018) · Dialyse aktuell · doi:10.1055/a-0669-8909
Knight, S. R. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4096-3.00016-7
Gaston, R. S. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4096-3.00018-0
Taler, S. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00034-2
Alteraciones del metabolismo de la glucosa en donante y receptor
Martínez-Juárez, I. A. (2020) · Revista Mexicana de Trasplantes · doi:10.35366/93494
Braun, W. E., Herlitz, L., Li, J., Schold, J. D., Poggio, E. D., Stephany, B. R., Fatica, R. A., Nally, J. V., Brown, K., Fairchild, R. L., et al. (2020) · Clinical Transplantation · doi:10.1111/ctr.14131
Yeter, H. H., Helvacı, Ö., Korucu, B., Gönen, S., Güz, G., & Derici, Ü. (2020) · Experimental and Clinical Transplantation · doi:10.6002/ect.2020.0130
Okihara, M., Takeuchi, H., Kikuchi, Y., Akashi, I., Kihara, Y., Konno, O., Iwamoto, H., Oda, T., Tanaka, S., Unezaki, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081670
Avoiding Steroids can be Successful Strategy After Kidney Transplantation
Augustine, J. J. (2009)
Transplantation: Issues and Controversies
Srinivas, T. R., & Schold, J. D. (2009)
…But Not All Patients Should be Steroid-Free Posttransplant
Dharnidharka, V. R. (2009)
Bang, J. B., Oh, C., Kim, Y. S., Kim, S. H., Yu, H. C., Kim, C., Ju, M. K., So, B. J., Lee, S. H., Han, S. Y., et al. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.576
Hypertension in the Kidney Transplant Recipient
Wadei, H. M., & Textor, S. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_20 · Cited by 1
The influence of kidney disease on protein and amino acid metabolism
Workeneh, B., & Mitch, W. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00047-1
Parrini, M., Angelini, D., Penno, G., & Rosati, A. (2018) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2011.1478
Knight, S. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00016-4
Service de néphrologie & hémodia-lyse, E. T. D. E. D. T. D. B. A., Kastali, M., Boulgheraif, A., Bezzi, L., BENKACIMI, N., Benrabeh, K., OUHARAOUA, I. B., & MAMERI, I. (2018) · Batna Journal of Medical Sciences (BJMS) · doi:10.48087/bjmsra.2018.5104
Defining a Steroid Withdrawal Protocol in a newly established Kidney Transplantation Unit
Moyo, O., Kumar, S. A., & Halawa, A. (2017) · Archives of Organ Transplantation · doi:10.17352/2640-7973.000009
Kamal, A., Elwasif, S. M., Mostafa, E., Abdelrahim, M., Elsherbiny, E., Shokeir, A., & Bakr, M. (2017) · Journal of The Egyptian Society of Nephrology and Transplantation · doi:10.4103/jesnt.jesnt_3_17
MacPhee, I. A. M., & van Gelder, T. (2012) · Wiley eBooks · doi:10.1002/9781118305294.ch16
News and issues that affect organ and tissue transplantation
Pondrom, S. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02547_2.x
Immunosuppression: Induction, Maintenance, and Steroid Avoidance Protocols
Kaiser, B. A., & Polinsky, M. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-07284-5_32
Parrini, M., Angelini, D., Pernio, G., & Rosati, A. (2011) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.1177/039493621102300313
Wiseman, A. C., & Cooper, J. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1690-7_10
Posttransplantation Monitoring and Outcomes
Gill, J., & Lan, J. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47794-9.00061-5
陈, 伯. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133621
Sizzling Issues in Clinical Renal Transplantation
Schold, J., Santos, A. H., Rehman, S., Magliocca, J. F., & Meier-Kriesche, H.-U. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/01.cjn.0000927088.58673.c3
Management of the Failing Pancreas Graft
Knight, R. J., Sadhu, A., & Gaber, A. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_69
Self-citationBova, S. E., Sparkes, T. M., Garcia, E., Szczepanik, A., Bromberg, J. S., Haririan, A., & Casale, J. P. (2024) · Clinical Transplantation · doi:10.1111/ctr.15241
Holdaas, H., KOBASHIGAWA, J. A., Fellström, B., & Jardine, A. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00040-2
Steroid Use in ABO-Incompatible Kidney Transplants: Withdrawal vs Maintenance
Shin, D. H., Kim, J. T., Kim, S. H., Park, K., Kim, D. G., & Lee, J. Y. (2025) · Annals of Transplantation · doi:10.12659/aot.947747
Clinical trials design and endpoints in liver transplantation
Laing, R. W., Boteon, A. P. C. D. S., & BOTEON, Y. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00009-5
Nagpal, R., Butler, K., Thal, N., Hobill, A., Gage, A. M., Javed, M., Karst, F., Khan, A. A., Needleman, A., Shirling, G., et al. (2025) · Transplant International · doi:10.3389/ti.2025.14852
Hayde, N. A., Blanchette, E. D., Bock, M., & Blydt‐Hansen, T. D. (2025) · Pediatric Transplantation · doi:10.1111/petr.70241
Evaluation and Management of Transplant-Associated Hyperglycemia
Bloom, R. D., & Moussallem, C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_21
Prednisone Avoidance After Abdominal Solid Organ Transplantation: A Narrative Review
Matar, A. J., Lake, J. R., Kandaswamy, R., & Matas, A. (2025) · Transplantation · doi:10.1097/tp.0000000000005572
Fragilité osseuse après transplantation rénale : effets des toxines urémiques et des médicaments
Batteux, B. (2022) · theses.fr (ABES) · doi:10.70675/2f05c086zc15bz407az866cz12a66620d076
Gill, J. S., Stiller, C., Lan, J. H., Jevnikar, A. M., Halloran, P. F., Rush, D., Nickerson, P. W., Cole, E., Matas, A. J., Formica, R. N., et al. (2026) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581261434082
Homeostasis of solute and water by the transplanted kidney
Mutig, K., Lederer, E. D., & Sambandam, K. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-12-815389-5.00040-x
Steroid Minimization in Kidney Transplantation: Rationale, Implementation, and Future Directions
Cheungpasitporn, W., Axelrod, D. A., Caliskan, Y., & Lentine, K. L. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.018
Krishnamoorthy, S., Kassis, Y. E., Concepcion, B. P., & Kyeso, Y. (2026) · Current Transplantation Reports · doi:10.1007/s40472-026-00532-9
Bachmann, Q., Aßfalg, V., & Renders, L. (2026) · Nephrologie aktuell · doi:10.1055/a-2856-7450
Hendren, E. M., Lan, J. H., Kadatz, M., Sridhar, V. S., Avgay, G., O'Donoghue, D., Farkas, V., Borg, J., Rojas, W., & Gill, J. S. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.10.029
Outcomes of Kidney and Pancreas Transplantation
Srinivas, T. R., Meier‐Kriesche, H., & Schold, J. D. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-642-9_7
Costello, A. L., & Batty, D. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-642-9_6
Metadata
- Authors
- Woodle, E. S., First, M. R., Pirsch, J., Shihab, F., Gaber, A. O., & Van Veldhuisen, P.
- Affiliations
- University of Cincinnati (US)
- Astellas Pharma (United States) (US)
- University of Wisconsin–Madison (US)
- University of Utah (US)
- Houston Methodist (US)
- Corresponding author
- Woodle, E Steve
- Venue
- Annals of Surgery
- Published
- 2008-10
- Volume
- 248
- Issue
- 4
- Pages
- 564-577
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2026860062
- Cited by
- 474
- References
- 29
- Citations by year
- 2026: 6 · 2025: 20 · 2024: 8 · 2023: 13 · 2022: 14 · 2021: 25 · 2020: 24 · 2019: 26 · 2018: 22 · 2017: 25 · 2016: 32 · 2015: 26 · 2014: 45 · 2013: 29 · 2012: 43
- FWCI
- 29.87
- Type
- journal article
- Language
- en
- Open access
- green
- works.bepress.com
- Licence
- cc-by
- Locations
- Annals of Surgery (publishedVersion)
- PubMed (publishedVersion)
- Journal of Bioresource Management (submittedVersion)
- Journal of Bioresource Management (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Keywords
- corticosteroid withdrawal, kidney transplantation, prednisone, acute rejection, graft loss, patient death, antibody-mediated rejection, renal function, immunosuppression, delayed graft function, deceased donor, living donor, long-term outcomes, corticosteroid-sparing immunosuppression
- MeSH terms
- Adolescent, Adult, Aged, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Glucocorticoids, Graft Rejection, Humans, Kidney Failure, Chronic, Male, Middle Aged, Prednisone, Prospective Studies, Time Factors, Kidney Transplantation, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.